Table 4.
Characteristics of patients in AKI nonrecovered and recovered group during follow-up periods
| Variables | AKI Nonrecovery | AKI Recovery | P Value |
|---|---|---|---|
| N | 19 | 16 | |
| Days from onset | 9 (7–14) | 7 (5–12) | 0.22a |
| Age | 64.0±8.1 | 64.5±14.7 | 0.89b |
| Sex (male) | 14/19 (73.7%) | 8/16 (50.0%) | 0.15c |
| Hypertension, % | 9/19 (47.4%) | 7/16 (43.8%) | 0.83c |
| Diabetes, % | 8/19 (42.1%) | 6/16 (37.5%) | 0.78bc |
| ACEI/ARB treatment history, % | 4/19 (21.1%) | 5/16 (31.3%) | 0.49c |
| Glucocorticoids treatment, % | 18/19 (94.7%) | 13/16 (81.3%) | 0.21c |
| Antibiotic treatment, % | 19/19 (100.0%) | 14/16 (87.5%) | 0.11c |
| Umifenovir treatment, % | 12/19 (63.2%) | 8/16 (50.0%) | 0.43c |
| Intravenous immunoglobulin therapy, % | 9/19 (47.4%) | 9/16 (56.3%) | 0.60c |
| Continuous KRT, % | 5/19 (26.3%) | 1/16 (6.3%) | 0.19d |
| Reexamined serum albumin, g/L | 25.9±5.9 | 31.3±5.9 | 0.01b |
| Reexamined lymphocytes, 109/L | 0.47 (0.32–0.85) | 0.93 (0.35–1.45) | 0.07a |
| Reexamined eosinophils, 109/L | 0.03 (0.00–0.13) | 0.04 (0.00–0.08) | 0.67a |
| SCR of baseline, μmol/L | 74.0 (61.0–89.0) | 72.5 (60.0–85.0) | 0.81a |
| COVID-19 grade | <0.001a | ||
| Moderate, % | 1/19 (5.3%) | 4/16 (25%) | |
| Severe, % | 0/19 (0.0%) | 6/16 (37.5%) | |
| Critically ill, % | 18/19 (94.7%) | 6/16 (37.5%) | |
| Stage of AKI | 0.001a | ||
| Stage 1 | 4/19 (21.1%) | 12/16 (75.0%) | |
| Stage 2 | 4/19 (21.1%) | 4/16 (25.0) | |
| Stage 3 | 11/19 (57.9%) | 0 | |
| Classification of AKI | 0.27d | ||
| Prerenal AKI | 0/19 (0) | 2/16 (12.5%) | |
| Rhabdomyolysis-induced AKI | 3/19 (15.8%) | 1/16 (6.3%) | |
| Intrinsic AKI | 16/19 (84.2%) | 13/16 (81.3%) | |
| Remission of proteinuria | 1/7 (14.3%) | 7/10 (70.0%) | 0.05d |
| Remission of hematuria | 1/7 (14.3%) | 2/6 (33.3%) | 0.56d |
Data are presented as number and percentage, mean±SD, or median (25th–75th percentiles). SCR, serum creatinine.
a
Wilcoxon rank-sum test.
b
t test.
c
Chi-square test.
d
Fisher exact test.